NASUS PHARMA LTD
NSRXNYSE AMERICAN🏆 #3782 by market capUS Equity
$3.31▼ $0.04 (−1.19%)
🌅 Pre-market$3.30▼ 0.30%Regular close · extended-hours price shown1h—
24h▼ 1.2%
7d▲ 5.1%
14d▲ 8.9%
30d▲ 7.5%
1y—
🏦Market Cap
$39M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
62
Fair
Trading Snapshot
- Day Range
- $3.30 – $3.33
- 52-Week Range
- $1.98 – $9.99
- Volume
- $2.12B
- Avg Volume
- $1.76B
- Shares Outstanding
- 11.7M
- Next Earnings
- Sep 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $860,360
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.87
- Dividend Yield
- —
Why Investors Own NSRX
- ✓High-growth profile — revenue up +37.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$4M▲ +40.8% YoY
Gross Margin (TTM)
28.0%▲ +2.9% YoY
Operating Income (TTM)
$903,148▲ +40.8% YoY
Free Cash Flow (TTM)
$1M▲ +40.8% YoY
About NASUS PHARMA LTD
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
62/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026